3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Breast Neoplasms
5
Polycystic Ovary Syndrome
2
Obesity
2
Leukemia, Myeloid, Acute
2
Head and Neck Neoplasms
2
Endometrial Neoplasms
2
Triple Negative Breast Neoplasms
1
Tracheal Diseases
1
TP53 Y220C Mutation
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Salivary Gland Neoplasms
1
Peripheral Nervous System Diseases
1
Pancreatic Neoplasms
1
Overweight
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Motor Activity
1
Mesothelioma
1
Meningioma
1
Medulloblastoma
1
Lymphoma
1
Lung Neoplasms
1
Localized Prostate Cancer
1
Leukemia
1
Leiomyosarcoma
1
Interventions
venetoclax
22
Cyclophosphamide
14
Cytarabine
12
Azacitidine
8
fludarabine
7
Daunorubicin
5
ruxolitinib
4
revumenib
4
Trimethoprim, Sulfamethoxazole Drug Combination
4
Dexamethasone
4
quizartinib
3
pirtobrutinib
3
gamma-Globulins
3
fludarabine phosphate
3
blinatumomab
3
Tacrolimus
3
Rituximab
3
Palliative Care
3
Granulocyte Colony-Stimulating Factor
3
Decitabine
3
Ciprofloxacin
3
Blood Specimen Collection
3
zanubrutinib
2
pembrolizumab
2
ibrutinib
2
aldesleukin
2
acalabrutinib
2
Watchful Waiting
2
Mycophenolic Acid
2
Melphalan
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Leukemia
×
Tablets
×
Clear all
NCT06643221
2024-10-16
Allo-X
University of Arizona
Phase EARLY_PHASE1
Recruiting
100 enrolled